Pre-made Claudiximab benchmark antibody ( Whole mAb, anti-CLDN18 therapeutic antibody, Anti-SFTA5/SFTPJ Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-109

Pre-Made Claudiximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-109-1mg 1mg 3090
GMP-Bios-ab-109-10mg 10mg Inquiry
GMP-Bios-ab-109-100mg 100mg Inquiry
GMP-Bios-ab-109-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Claudiximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody
INN Name Claudiximab
TargetCLDN18
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesGanymed Pharmaceuticals
Conditions Approvedna
Conditions ActiveGastric cancer;Oesophageal cancer;Pancreatic cancer
Conditions DiscontinuedSolid tumours
Development Techna